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Abstract: Community-acquired pneumonia (CAP) is the most common infectious disease related cause 
of death worldwide despite the use of effective antimicrobials. Much of the morbidity and mortality seen 
in CAP patients at high risk of death has been attributed to exaggerated host responses that result in 
bystander tissue damage and organ failure. Therefore there is great need to further understand the effect of 
hyperinflammatory phenotypes on CAP outcomes and develop adjuvant therapy that can attenuate excessive 
inflammatory responses without compromising host defense. Furthermore, there is growing concern 
regarding the development of antimicrobial resistance and recent research aims to modulate immune 
mechanisms that boost pathogen killing and clearance. In this review we summarize the growing body 
of evidence for the use of adjuvant immunomodulators in the treatment of CAP and highlight emerging 
immunomodulators that have been tested in pre-clinical studies, which need to be evaluated and developed 
for clinical trials. In summary, current evidence supports the use of macrolide combination antibiotic therapy 
and unless contraindicated continuation of pre-admission statin and antiplatelet therapy. Corticosteroids are 
beneficial in the context of septic shock and critical illness related adrenal insufficiency and may be of benefit 
to individuals with severe CAP and a hyperinflammatory phenotype given the potential for improving 
patient-centered and economic outcomes with negligible adverse effects. Despite much promise in pre-
clinical work, many clinical trials of drugs targeting the coagulation pathways have unfortunately failed to 
demonstrate clinical benefits in humans. Results of trials evaluating aspirin, intravenous immunoglobulin 
(IVIg) and thrombomodulin are awaited and may yet influence practice, whilst further identification of 
inflammatory phenotypes will in the future allow personalized approaches and identify subgroups of patients 
that may respond to adjuvants that have previously not demonstrated favorable outcomes when used in 
heterogeneous cohorts.
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Introduction
Despite effective antimicrobials, community-acquired 
pneumonia (CAP) remains a significant cause of morbidity 
and mortality (1). In 2012 the annual European incidence 
of CAP was 150–170 episodes per 100,000 people (2). 
The incidence progressively rises in older age groups, 
to roughly 2% in those aged 81 years and over compared 
to 0.2% in those aged 31–40 years, and in more deprived 
social groups with pneumonia around 45% more common 
in the most deprived social quintile compared to the least (3). 
Between 22% and 42% of those with CAP require hospital 
admission (4), accounting in 2015–2016 for 248,916 out of 
16.3 million UK National Health Service (NHS) hospital 
admissions (5). This compares with 674,000 hospital 
admissions due to pneumonia of a total of 12.2 million 
in the US (6). Pneumonia and influenza were the 6th 
and 4th commonest causes of death in 2013 in UK males 
and females respectively, accounting for 5–6% of deaths 
annually or an age-standardized mortality rate per million 
population of 614 in males and 473 in females (7). In the 
US the adjusted figure is 151 per million population overall, 
with a similar male predominance, causing 2.1% of all 
deaths, ranking 8th commonest (8).
Austrian and Gold demonstrated the significant 
improvement in outcomes following the introduction 
of antimicrobial therapy for uncomplicated bacteremic 
pneumococcal pneumonia, with overall mortality reduced 
from 80% to 17% (9). However despite advances over 
the subsequent 50 years, mortality remains high at 12% 
for bacteremic pneumococcal pneumonia (10), and as 
high as 21–58% amongst the severe CAP subgroup (11). 
Therefore, there is great need to focus our research efforts 
on identifying novel therapeutic strategies that can be used 
in combination with antimicrobials to reduce mortality 
from CAP.
A role for immunomodulation
With current culture-based microbiological techniques 
often the causative organism is not identified, but when 
detected the commonest causative community-acquired 
pathogen is Streptococcus pneumoniae, and viruses including 
Influenza are increasingly being recognized as a cause of 
primary viral pneumonia or secondary bacterial pneumonia 
(1,12). Legionella species, Staphylococcus aureus, enteric 
bacteria and other organisms, for example Klebsiella 
pneumoniae, account for a disproportionate number of 
ICU admissions compared to their overall incidence. 
Antimicrobial resistance varies markedly, with rates of 
resistance for S. pneumoniae over 30% in Spain and Greece 
but below 3% in Germany (13). However studies suggest 
that clinically-significant antibiotic resistance is a rare cause 
of treatment failure in CAP and is not an independent 
risk factor for poor prognosis (14). In contrast, it has been 
shown that patients with a delayed time to clinical stability 
over 3 days have a persistently elevated level of plasma 
cytokines, compared to the rapid decline seen in those who 
improve quickly (15). Thus, these factors combined drive 
interest in the impact of underlying host factors in the 
response to infection and the potential to modulate these 
to improve outcomes. Much as in the new sepsis guidelines 
(16), where the stress is on the dysregulated host response 
to infection defining sepsis and driving the associated 
mortality, a similar theory is appropriate to severe CAP 
where excess local inflammation causing tissue destruction 
and alveolar-endothelial capillary barrier disruption 
precipitates lung injury (17), systemic inflammation 
underpins sepsis (18), and activation of coagulation triggers 
disseminated intravascular coagulation (DIC) (19), with 
the latter two causing microthrombi and microvascular 
dysfunction leading to multiorgan failure. Likewise, the 
challenges in advancing management and improving 
survival come firstly in identifying this cohort early and 
differentiating from those with CAP with a high likelihood 
of survival from the outset, and secondly in identifying the 
pathophysiological mechanisms defining this cohort and 
appropriately targeting these.
Immune, inflammatory and coagulation response 
to respiratory tract infection
The immune response to respiratory pathogens is complex 
and is reviewed in detail elsewhere (20-23). Here we 
provide a concise summary to highlight important immune 
and inflammatory pathways particularly those related to 
innate immunity. Alveolar macrophages are resident in the 
lung and play important roles in homeostasis, prevention 
of inflammation through an inhibitory interaction with 
the epithelium, and in daily clearance of small numbers 
of pathogens that are inhaled or aspirated. However, in 
the presence of large numbers of pathogens they become 
overwhelmed and are unable to control the infection, 
requiring the recruitment of immune cells (24). During 
exposure to respiratory tract pathogens, pathogen-derived 
pathogen-associated molecular patterns (PAMPS) and host-
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derived damage-associated molecular patterns (DAMPS) 
bind Toll-like receptors (TLRs) on epithelial cells, and 
alveolar macrophages, causing release of nuclear factor 
kappa B (NF-κB)-transduced pro-inflammatory cytokines, 
including tumour necrosis factor (TNF), interleukin (IL)-1β, 
and IL-6 (25), and chemokines such as CXCL8 and CCL2 
to recruit neutrophils and monocytes, respectively, from 
the pulmonary circulation to the airspaces. Neutrophils 
kill the pathogens primarily via phagocytosis, whereby 
internalization of the pathogen into a phagosome results 
in degranulation, release of antibacterial and lytic enzymes 
and production of reactive oxygen species in the oxidative 
burst response (15). Additionally, neutrophils can release 
DNA-based neutrophil extracellular traps, which can trap 
pathogens, kill bacteria via histones and antimicrobial 
granular proteinases and opsonize fungi (26). Once 
activated, neutrophil apoptosis and subsequent clearance by 
macrophages is necessary for de-escalation of the response. 
Dendritic cells exposed to pathogens initiate the adaptive 
immune response, migrating to the lymph nodes to recruit 
helper T lymphocytes and induce memory T lymphocytes.
Although this inflammatory response is essential for 
control of the infection and clearance of pathogens, an 
uncontrolled or exaggerated inflammatory response can 
result in bystander tissue injury. Therefore, an appropriate 
balance between cytokine production and neutrophil 
activation successfully combating bacterial infection and 
overproduction and dysregulation resulting in excessive 
lung injury is key. When measured, persistent cytokine 
elevation, particularly IL-6 but also IL-10, correlates with 
mortality even following hospital discharge (27,28). Further, 
it has been demonstrated that as compared to patients with 
non-severe CAP, patients with severe CAP at the time of 
hospital admission have significantly elevated plasma levels 
contributing to an exaggerated systemic inflammatory 
response (29). This is in keeping with studies suggesting 
that failure of neutrophil depriming in the lungs results in 
higher systemic levels of activated neutrophils in patients 
with the acute respiratory distress syndrome (ARDS) (18).
Importantly, there is a close relationship between 
inflammation and coagulation allowing haemostatic 
containment to contribute to the initial host response to 
infection. Activation of the coagulation cascade by tissue 
injury or inflammation secondary to infection occurs by 
stimulating the expression of tissue factor (TF) on the 
surface of mononuclear cells, fibroblasts, alveolar and 
epithelial cells (30). When TF expressed on cells is exposed 
to blood it activates and binds to the inactive zymogen 
factor VII (FVII). The TF-FVIIa complex then initiates 
the TF dependent pathway of coagulation by activating 
FX and binding to FXa, forming the TF-FVIIa-FXa 
ternary complex, which together with thrombin-induced 
positive feedback activation of FV and FVIII, results in 
significant thrombin generation and fibrin cross-linking. 
Platelets, activated via thrombin or directly via platelet-
activating factor, are also involved in both coagulation 
and inflammation, expressing P-selectin which both binds 
neutrophils and augments macrophage TF expression via 
NF-κB (31,32).
Linking inflammation and coagulation are the protease-
activated receptors (PARs), a group of seven transmembrane 
G protein-coupled receptors which undergo proteolytic 
cleavage of the extracellular N-terminus and the unmasking 
of a previously cryptic tethered ligand, which interacts 
with the second extracellular loop of the receptor resulting 
in conformational change of the receptor and initiates 
cell signaling via the recruitment of heterotrimeric G 
proteins (30). Thrombin acts via PAR-1 to induce the 
release of pro-inflammatory cytokines (such as IL-1β) and 
chemokines (including CXCL1, CCL2 and CCL7) (33), 
and at high concentrations stimulates platelets via PAR-1 
and PAR-4 to release further platelet agonists, chemokines 
and growth factors, potentiating both inflammation and 
coagulation and contributing to endothelial disruption (34). 
In contrast, epithelium-bound activated protein C (APC) 
acts via PAR-1 to downregulate inflammation and improve 
host defense to endotoxins (35,36).
Coagulation is normally regulated by antithrombin, 
activation of protein C, and TF pathway inhibitor (TFPI). 
However, during severe infection these mechanisms 
are impaired. Consumption and diminished production 
reduce the levels of the former two, activated neutrophils 
produce elastases degrading antithrombin and TFPI, 
downregulation of endothelial thrombomodulin prevents 
activation of protein C, and increased plasma C4b binding 
protein levels as an acute phase reactant result in a relative 
protein S deficiency. Furthermore, there is an increase in 
plasminogen activator inhibitor type-1 (PAI-1) resulting 
in reduced plasminogen activation and hence reduced 
fibrinolysis (37,38).
Targeting inflammation pathways
Macrolides
In addition to antimicrobial effects on both typical (e.g., 
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S. pneumoniae) and atypical (e.g., Mycoplasma pneumoniae) 
respiratory tract pathogens, macrolides are known to 
impact on the host-pathogen interaction both directly 
and  by  immunomodula tory  e f f ec t s  v i a  mul t ip le 
mechanisms including altering the balance in favour of 
anti-inflammatory cytokines, facilitating phagocytosis 
of apoptotic cells by alveolar macrophages, reducing 
recruitment and adhesion of both neutrophils and 
T-cells, and increasing neutrophil degranulation thereby 
enhancing bactericidal activity (39). First noted following 
striking improvement in outcomes of patients with diffuse 
panbronchiolitis (40), macrolides are now frequently used 
for long-term reduction of inflammation in bronchiectasis 
and chronic obstructive pulmonary disease as well as acutely 
for their immunomodulatory properties in CAP.
In a recent meta-analysis of 10,000 critically ill patients 
with CAP caused by a range of pathogens, macrolide 
therapy reduced the overall relative risk of mortality 
by 18% versus non-macrolide containing antibiotic 
regimens (41). A trend towards reduced mortality was 
maintained in subgroup analyses of patients requiring 
mechanical ventilation and in those managed with 
macrolide/beta-lactam rather than fluoroquinolone/
beta-lactam combination therapy, though not when the 
causative pathogen was limited to S. pneumoniae, when only 
prospective studies were included, or in a smaller group 
with septic shock. This effect persists regardless of the 
presence of ex vivo macrolide resistance (42). Furthermore, 
observational data from the US, Europe and Latin America 
shows a significant reduction in mortality in ICU patients 
managed with a macrolide with an odds ratio of 0.45 (95% 
CI, 0.31–0.66) (43). This effect was lost when assessing 
patients admitted to ward level care. Similarly, a recent 
prospective study assessing patients admitted with CAP but 
not requiring ICU showed beta-lactam monotherapy to be 
non-inferior to either beta-lactam/macrolide combination 
or fluoroquinolone monotherapy (44), suggesting that 
macrolides are beneficial in those with severe inflammatory 
disease and increased risk of death.
Corticosteroids
Corticosteroids may be helpful in managing bronchospasm 
related to underlying airways disease or de novo due to the 
infection itself, or may be beneficial in patients in whom 
there is an associated critical illness-related corticosteroid 
insufficiency (CIRCI) (45,46). Moreover, the wider role 
of steroids as an adjunct in abrogating the inflammatory 
response associated with poorer outcomes in CAP is of 
significant interest. A number of meta-analyses have evaluated 
the available evidence. A Cochrane review identified six studies 
up to 2010 totaling 437 participants (47). These are disparate 
trials studying variously adults and children, differing 
corticosteroid regimens including with inhaled budesonide, 
and a range of outcomes. The overall conclusion was that 
despite failing to improve mortality, steroids may accelerate 
time to clinical stability, improve oxygenation, reduce the 
need for mechanical ventilation and decrease the rate of 
relapse. However the data quality is poor with only two 
studies deemed to be of high quality and therefore it is 
difficult to extrapolate findings to clinical practice. More 
promisingly, analysis of 9 randomized controlled trials 
(RCTs) of 1,001 patients with either severe or mixed CAP 
managed with varying corticosteroid regimens up to 2011 
showed no overall mortality benefit, but in subgroup 
analyses a reduction in mortality was seen in patients with 
severe CAP (odds ratio 0.26) and in those given steroids for 
longer than 5 days (odds ratio 0.51) (48).
Much of the criticism of the available data revolves 
around either the wrong patient cohort being studied, who 
were unlikely to reflect a hyperinflammatory phenotype, 
or an inappropriately large dose or short duration 
corticosteroid regimen being used. One of the earlier RCTs 
demonstrating a benefit addressed this by enrolling Italian 
patients with severe CAP as defined by the old American 
Thoracic Society (ATS) criteria and an average C-reactive 
protein (CRP) of 290 mg/L (placebo) or 550mg/L 
(intervention), managed with hydrocortisone as a 200 
mg bolus followed by 240 mg/d infusion for 7 days (49). 
The trial was actually stopped at the interim analysis 
because of favorable outcomes in the intervention arm, 
with hydrocortisone after 8 days effecting a significant 
improvement in ratio of arterial oxygen partial pressure to 
fraction of inspired oxygen (paO2:FiO2), and a significant 
reduction in radiographic infiltrates, CRP, multiorgan 
dysfunction scores, and incidence of delayed septic shock. 
However only 46 patients were studied, there was an albeit 
non-significant increase in comorbidities in the placebo arm 
and cytokine levels were not measured.
A more recent RCT randomized 120 Spanish patients 
with severe CAP as defined by the modified Infectious 
Diseases Society of America (IDSA)/ATS criteria or 
pneumonia severity index (PSI) class V and CRP greater 
than 150 mg/L to receive methylprednisolone 0.5 mg/kg 
12 hourly for 5 days or placebo (50). Whilst the primary 
outcome of a reduction in treatment failure was achieved, 
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this was the result of a significant reduction in late (72–120 h) 
radiographic progression in the intervention arm, which the 
authors argue is a surrogate for mortality requiring fewer 
participants to achieve the necessary power. There were 
no statistically significant differences in other measures of 
early or late treatment failure or in secondary outcomes 
including time to clinical stability, ICU and hospital length 
of stay, and in-hospital mortality. Furthermore, except for 
a significant reduction in CRP at day 3 in the intervention 
arm, there was no significant difference between arms at 
either day 3 or 7 of procalcitonin, IL-6, IL-8 or IL-10. 
Limitations of the study include the non-significantly higher 
rate of chronic pulmonary disease and viral aetiologies in 
the intervention arm, the low rates of macrolide usage and 
delays to administering first dose of antibiotics in both 
groups.
In contrast, a contemporary study included 785 Swiss 
patients admitted with CAP of all severities with similar 
average baseline CRP of around 160 mg/L, randomising 
them to receive either prednisone 50 mg daily for 7 days or 
placebo (51). Prednisone reduced time to clinical stability 
from 4.4 to 3.0 days with no increase in pneumonia-related 
complications to 30 days. It also resulted in a significant 
reduction in CRP concentrations at days 3, 5 and 7, but 
this did not impact on other outcomes including mortality, 
length of ICU and hospital stay, and readmission.
The most recent meta-analysis includes these studies 
amongst 9 RCTs and 6 cohort studies, finding that 
the cumulative data available still lacks power to make 
significant conclusions (52). There was no difference in 
mortality amongst the RCTs, nor amongst the RCTs and 
cohort studies enrolling patients with severe CAP only. 
Pooling of data from 3 RCTs in which patients were given 
a loading dose of steroids did show a mortality benefit with 
a relative risk of 0.23 (95% CI, 0.09–0.63), but the overall 
dataset is small. Despite the inconsistent reporting of data, 
corticosteroids did tend to reduce length of stay, duration 
of intravenous antibiotics and time to clinical stability, and 
there was a signal of reduced rates of ARDS. Finally the 
largest dataset is an observational study of 6,925 patients 
with pneumonia, in whom a mortality benefit appeared to 
be restricted to cases complicated by septic shock (53), and 
reflects previous findings for the use of corticosteroids in 
sepsis (54).
Despite the lack of efficacy in reducing mortality, there 
is a signal that corticosteroids may reduce other clinically 
relevant measures including lengths of stay and time to 
clinical stability, which are beneficial both to the patient 
and in terms of health economics. It is reassuring that aside 
from increased hyperglycemia in some studies, there are 
no significant adverse effects associated with steroid use 
either in terms of pneumonia-related complications or 
systemic sequelae. However, until a larger body of good 
quality evidence is available many clinicians will still opt 
not to use them in the absence of septic shock. Further 
research into corticosteroid use is still required particularly 
as it remains unclear whether to target the severe CAP 
subgroup as currently defined or all patients with CAP, what 
the optimum corticosteroid and dosing regimen is, and if 
more specific patient phenotyping is required to identify 
corticosteroid responders.
Statins
Beyond  l ip id- lower ing  proper t i e s ,  s t a t in s  have 
immunomodulatory effects including improvement of 
endothelial dysfunction, downregulation of endothelial 
adhesion molecules, reduced cytokine production and 
reduced neutrophil  recruitment (55,56). This is supported 
in vivo by data showing a reduction in IL-6 and TNF in 
hospitalized patients with bacterial infections managed with 
simvastatin compared to placebo in addition to standard 
care (57). There is however a conflicting body of evidence 
for their impact in CAP with population-based studies 
in primary care suggesting a lower risk of developing 
pneumonia in patients taking statins (58) and similar 
observational studies suggesting a reduced 30-day mortality 
in patients admitted with pneumonia (59). However, a more 
recent US primary care case-control study of over 65s found 
no reduction in risk of CAP associated with statins (60). 
The study excluded nursing home residents, whom the 
authors suggest are both at a higher risk of developing 
pneumonia but also perhaps less likely to be prescribed a 
statin, and therefore previous studies not doing likewise 
may have been subject to ‘healthy user’ bias.
Despite adjusting for multiple confounders, there is an 
argument that the benefit seen is simply in the reduction of 
secondary cardiovascular events due to supply and demand 
mismatch in myocardial perfusion (61). However in a study 
of patients hospitalized with an acute coronary syndrome 
or ischemic stroke, commencing a statin within 90 days of 
discharge was associated with a significant reduction in the 
risk of sepsis, severe sepsis and fatal sepsis with hazard ratios 
of 0.81, 0.83 and 0.75 respectively, an effect not seen with 
other lipid-lowering medications (62).
There is limited data studying statins as an intervention 
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in CAP and these studies are needed since there is a 
suggestion from a small non-interventional study that 
statins may be associated with enhanced efferocytosis (63) 
which could lead to better recovery from pneumonia. 
Furthermore, a recently published study demonstrated 
that high-dose (80 mg) simvastatin enhances the migratory 
accuracy of neutrophils in vitro from elderly individuals 
with CAP, but only in those with less severe disease (64), 
corroborating previous findings that statins are not 
beneficial in severe sepsis and ARDS (65-67). Importantly, 
it is not known what effect simvastatin-enhanced neutrophil 
migratory accuracy will have on important clinical 
outcomes of individuals with CAP and future prospective 
interventional trials are needed. Monitoring for adverse 
effect will however be required, since high-dose simvastatin 
may be associated with detrimental adverse effects such as 
elevated creatinine kinase or hepatic transaminases as seen 
in the HARP-2 trial (67).
Intravenous immunoglobulins (IVIg)
Patients with CAP have been found to have lower 
levels of immunoglobulin (Ig) G and IgA compared to 
healthy subjects (68). Progressively lower levels of all 
IgG subsets and IgA correlate with severity of CAP in 
immunocompetent individuals as determined by need 
for ICU admission and CURB-65 score, and total IgG is 
independently associated with need for ICU admission even 
when accounting for CURB-65 score and cardiorespiratory 
comorbidities (69). Interestingly there is no difference 
between patients admitted to the ward and those managed 
as an outpatient, suggesting that hypogammaglobulinemia 
may distinguish the ICU cohort (69). Additionally, these 
deficiencies may persist for as long as 9 months post-
infection (70).
The effects of IVIg on outcomes from CAP are not 
well known and results of the CIGMA study assessing use 
of IgM-enriched polyclonal IVIg in severe CAP requiring 
mechanical ventilation are currently awaited (71). In 
sepsis IVIg may be beneficial by neutralising bacterial 
toxins, improving bacterial opsonization and modulating 
complement activation (72). However, current data do not 
strongly support its use. One meta-analysis found a 21% 
relative risk reduction for mortality using polyclonal 
IVIg in patients with sepsis or septic shock (73). 
However in another study IVIg given on days 0 and 
1 in all-cause severe sepsis had no impact on 7- or 28-
day mortality, or IL-6 and TNF receptor levels (74). 
A contemporary systematic review found that although overall 
there was a reduction in mortality in trials of polyclonal 
IVIg, when only high-quality data was included there was 
no benefit (75). Similarly, a subsequent Cochrane review also 
showed polyclonal and IgM-enriched IVIg reduced mortality in 
sepsis and septic shock in adults with a relative risk of 0.81, but 
that when only 5 trials adjudged to have a low risk of bias were 
included, no such effect was seen (76).
In Japan, where polyclonal IVIg can be considered for use 
in sepsis for up to 3 days, a retrospective database analysis 
of patients with septic shock due to pneumonia requiring 
mechanical ventilation showed no benefit to IVIg in terms 
of 28-day or in-hospital mortality, ventilator-free days or 
catecholamine-free days either in raw data or with propensity 
matching (77). Immunoglobulin levels are not reported and it is 
interesting that again use of macrolides was low at around 8% in 
both groups. This may reflect an overall lack of efficacy or that 
the wrong cohort was reviewed and that there may be a benefit 
to IVIg in patients identified by low levels prior to establishment 
of either respiratory failure requiring mechanical ventilation or 
sepsis. Such a theory is supported by data suggesting that as with 
antibiotics in sepsis, efficacy of IVIg is time-dependent (78).
Targeting coagulation pathways
A significant body of evidence from pre-clinical work 
suggests that targeting coagulation pathways can modulate 
the inflammatory response to infection. In clinical studies, 
much of the data evaluates either patients with sepsis 
rather than CAP per se, or patients developing ARDS. 
However, given the high proportion of these cohorts with 
an underlying diagnosis of CAP, these data are useful to 
extrapolate or conduct retrospective subgroup analyses to 
inform future research directions in CAP management. 
Given the concerns regarding adverse bleeding events 
with systemic administration of anticoagulants, there 
is a significant body of work looking at nebulized drug 
delivery to the lungs, which may permit higher therapeutic 
doses to be delivered to the site of action. The majority 
of these studies used animal models of S. pneumoniae or 
lipopolysaccharide-induced pneumonia and have demonstrated 
reduced activation of coagulation and inflammation in the 
lungs without systemic adverse effects (79). Human studies 
are therefore greatly desired.
APC [drotrecogin alfa (activated)]
As  de sc r ibed  above ,  p ro te in  C  a s soc i a t ed  w i th 
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thrombomodulin on the epithelial surface is activated 
by thrombin and regulates coagulation by inhibiting FV 
and FVIII, promotes fibrinolysis by inhibiting PAI-1, 
and inhibits macrophage TNFα production. In humans 
it causes a reduction in d-dimer and IL-6 levels in 
patients with severe sepsis, implying a downregulation 
of both coagulation and inflammation pathways (80). 
The PROWESS trial was terminated early for efficacy, 
demonstrating a significant reduction in 28-day mortality 
in patients with severe sepsis managed with adjunctive 
APC [drotrecogin alfa (activated)] irrespective of baseline 
levels of protein C, with a relative risk reduction of 
19.4% (80). Subgroup analysis showed this benefit was 
sustained only in those patients with an Acute Physiology 
and Chronic Health Evaluation (APACHE II) score ≥25 
or 2 or more organ failures (81). APC was thus approved 
for adjunctive use in patients with sepsis and a high risk 
of death or multiple organ failure and adopted into the 
surviving sepsis campaign guidelines (82,83). However, 
the subsequent ADDRESS study showed no overall 
mortality benefit in patients at lower risk of death 
and subgroup analysis actually suggested an increased 
mortality in patients with an APACHE II score ≥25 
who were randomized to APC (84). Adverse events were 
seen in all studies with serious bleeding significantly 
higher with APC regardless of use of concurrent 
heparin, in PROWESS at 3.5% compared to 2.0% 
with placebo, though rates of thrombosis were similar. 
Furthermore, in the ENHANCE open-label trial, the 
serious bleeding rate was higher with APC at 5.5% and 
there was a higher rate of intracranial haemorrhage (85), 
suggesting that this strategy may lead to harm in some 
patients. Subsequently therefore, the PROWESS-SHOCK 
trial was mandated, and found no benefit in 28- or 90-day 
mortality from APC given to patients with septic shock 
and signs of hypoperfusion either as a whole or in a priori 
defined subgroups (86).
A large proportion (54% and 44%) of patients in the 
PROWESS and PROWESS-SHOCK trials had a focus 
of infection within the lungs and post hoc analysis of the 
PROWESS trial assessed the impact of APC in those 
patients with CAP (87). They were able to identify 35.6% 
of patients as having sepsis related to CAP, with a slightly 
higher proportion within the APC arm, of whom around 
a quarter isolated S. pneumoniae. Interestingly, IL-6 levels 
were higher in patients with S. pneumoniae in whom 
upwards of 60% were bacteremic, roughly double the rate 
in CAP of other aetiologies, but there was no difference 
in either baseline markers of illness severity or mortality. 
Unadjusted data showed improved 28-day mortality 
in patients with CAP with a relative risk of 0.72, (95% 
CI, 0.55–0.94) but there was no statistically significant 
difference at 90 days. Further subgrouping showed the 
benefit to be limited at 28 days to CAP patients with 
APACHE II score ≥25, PSI score ≥4 or requiring both 
vasopressor and ventilatory support, and by 90 days only 
those with APACHE II score ≥25 continued to have 
a mortality benefit. However following PROWESS-
SHOCK, drotrecogin alfa (activated) has been withdrawn 
from the market.
TFPI (tifacogin)
Recombinant TFPI (rTFPI; tifacogin) administered 
in sepsis may help restore appropriate regulation of 
coagulation and prevent endothelial injury, which might 
be particularly beneficial in reducing acute lung injury, 
although the mechanisms of action are debated. The 
OPTIMIST phase III trial of rTFPI in severe sepsis 
showed no overall benefit in patients with an international 
normalized ratio (INR) ≥1.2 despite evidence of biological 
activity, although contrary to phase II data there was a 
benefit in the smaller group of patients with INR <1.2, 
with increased rates of serious bleeding compared to 
placebo regardless of INR (88). One explanation for the 
lack of benefit is that doses causing significant bleeding 
may be lower than that required to regulate inflammation, 
thus precluding efficacious doses being administered (89). 
Post hoc subgroup analyses however highlighted a 
benefit in patients with documented bacteremia or 
pneumonia, particularly when concurrent heparin was not 
administered.
The signal  of  benefit  in pneumonia led to the 
CAPTIVATE trial assessing 2 doses of rTFPI versus 
placebo in patients with severe CAP as defined by the 
IDSA/ATS criteria not on concurrent heparin (90). The 
higher dose arm was discontinued early due to futility, but 
in the final results, there was equally no mortality benefit 
to rTFPI at the OPTIMIST dose regardless of severity 
as defined by APACHE II or PSI. There was also no 
difference in risk of deteriorating to require mechanical 
ventilation, developing ARDS, or developing DIC. It is 
noteworthy however, that there was a pre-defined protocol 
for interrupting rTFPI infusion in response to rising 
INR or falling platelet count and when it is considered 
that there was no difference in adverse events including 
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bleeding between the intervention and placebo arms, it 
may be that this protocol resulted in delivery of inadequate 
doses thereby protecting patients from harm but reducing 
efficacy.
Antithrombin III (ATIII)
A number of small studies demonstrated a mortality benefit 
of ATIII in sepsis, particularly in the more critically unwell 
and shocked patients (91). The KyberSept phase III trial 
was therefore undertaken to explore the use of high-dose 
plasma-derived ATIII in patients with severe sepsis (92). 
This demonstrated no overall benefit to 28-day mortality, 
although post hoc subgroup analysis showed an improved 
90-day mortality in patients not given concurrent heparin 
and in those with a higher mortality as predicted by the 
Simplified Acute Physiology Score (SAPS II). There was 
also a significantly higher risk of bleeding, exacerbated in 
the group co-administered heparin. The trial was criticized 
for failing to enrol patients as critically ill as intended, which 
given previous data may have had an impact on the expected 
efficacy, to achieve the intended supraphysiological levels 
of ATIII, and to protocolize heparin coadministration. A 
Cochrane review found there to be an associated bleeding 
risk and the available evidence to be of a low quality and 
not currently supportive of using ATIII in critically ill 
patients, including those with sepsis (93). A Japanese 
retrospective database analysis of ATIII in patients with 
severe pneumonia and sepsis-associated DIC (note cases not 
confirmed as community-acquired) has suggested improved 
28-day mortality with an adjusted odds ratio of 0.85 (95% 
CI, 0.75–0.97) in the propensity-matched groups, and 
additionally increased ventilator-free days (94). However 
such evidence cannot support widespread use of ATIII in 
CAP and prospective RCTs are required.
Thrombomodulin
The safety and bioactivity of recombinant thrombomodulin 
in sepsis associated with DIC has been demonstrated in a 
phase 2 trial, with a trend of improved mortality particularly 
in patients with dysfunction of at least one organ system (95). 
Interestingly case reports and small studies,  both 
retrospective and prospective, suggest a mortality benefit 
of recombinant thrombomodulin in patients with acute 
exacerbations of idiopathic interstitial pneumonia (96-98), 
hinting at a benefit in reducing pulmonary inflammation in 
addition to effects on DIC. A similar Japanese retrospective 
analysis to that for ATIII found no effect on 28-day 
mortality of recombinant thrombomodulin given to patients 
with severe CAP and sepsis-associated DIC, compared to 
a propensity-matched cohort (99) and therefore we now 
await the results of a phase 3 trial in severe sepsis with 
coagulopathy which is currently recruiting (100).
Antiplatelet agents
As with statins, it is likely that continuing antiplatelet 
therapy during CAP helps mitigate the risk of secondary 
cardiovascular events. Beyond this however, the potential 
of this drug class to inhibit the contribution of platelets to 
both excessive coagulation and inflammation in CAP has 
prompted further investigation. Aspirin downregulates 
NF-κB, inhibiting the cascade of inflammatory cytokine 
production (101), acts on endothelial nitric oxide synthase to 
increase nitric oxide levels impairing neutrophil recruitment 
and microthrombi formation (102), and induces production 
of aspirin-triggered lipoxins which exert anti-inflammatory 
effects (103).
A prospective study of Italian patients with a mean age 
around 75 years presenting with CAP of all severities stratified 
by pre-admission use of aspirin found twice as many patients 
were not taking aspirin, and that patients not taking aspirin 
were significantly more likely to have severe CAP with 
evidence of acute lung injury at baseline and more likely to 
have organ dysfunction, severe sepsis or septic shock (104). 
Following propensity matching, an increased 30-day mortality 
was demonstrated in the non-aspirin group with hazard ratio 
2.07 (95% CI, 1.08–3.98; P=0.029). A similar prospective 
analysis of patients with ARDS using multivariate logistic 
regression analyses demonstrated that patients receiving 
aspirin either pre-hospitalization or during their admission had 
a reduced risk of in-ICU mortality with an odds ratio of 0.38 
(95% CI, 0.15–0.96; P=0.04) (105). This effect was not noted 
when patients taking both aspirin and statins were evaluated, 
suggesting that the benefit is unlikely due to decreased 
cardiovascular events. Furthermore, two recent meta-analyses 
of cohort studies agree that antiplatelet agents in critically ill 
patients are associated with decreased mortality, incidence of 
ARDS and mechanical ventilation (106,107).
There are a number of trials of aspirin as an intervention 
currently ongoing, including one assessing the incidence of acute 
lung injury in medical “at risk” patients given aspirin (108), one 
assessing oxygenation in patients with established ARDS given 
aspirin 75 mg (109), and one assessing the efficacy of aspirin 
75 mg and 1,200 mg in reducing induced lung inflammation 
Annals of Research Hospitals, 2017 Page 9 of 17
© Annals of Research Hospitals. All rights reserved. Ann Res Hosp 2017;1:33arh.amegroups.com
in healthy volunteers (110). Unfortunately, a RCT designed to 
assess the mortality benefit of commencing ticagrelor de novo 
in patients with severe CAP has recently terminated having 
failed to recruit sufficient patients (111).
Other immunomodulators
Pattern recognition receptors
Pattern recognition receptors including TLRs play a 
key role in response to infection with PAMP recognition 
eliciting the initial innate immune response to eradicate a 
pathogen and PAMP and DAMP recognition contributing 
to propagation of the inflammatory response. In animal 
models, different TLRs have been associated with a variety 
of both infectious and inflammatory or autoimmune 
diseases. For example, TLR4 has been implicated in 
endotoxemia-induced systemic inflammation and sepsis, 
but is required for response to influenza A, S. pneumoniae, 
Haemophi lus  inf luenzae,  Klebs ie l la  pneumoniae  and 
Mycobacterium tuberculosis infections (112-114). The anti-
inflammatory nature of inactivated alveolar macrophages 
conveys a higher threshold for activation of innate immunity 
within the respiratory tract. Thus agonism of TLRs may 
upregulate the response to pathogen exposure helping 
prevent infection or improve pathogen clearance, whilst 
antagonism may inhibit the deleterious hyperinflammatory 
response.
A number of animal models have demonstrated a 
benefit to such strategies. Separate monoclonal antibodies 
to TLR2 and TLR4 when administered subcutaneously 
successfully reduced mortality in polymicrobial models of 
intra-abdominal sepsis in mice concurrently treated with 
antibiotics, although the effect was most marked when the 
antibodies were administered prior to induction of sepsis 
and was reduced though still statistically significant when 
given 3 h after (115). However, in humans, in the phase III 
ACCESS trial, eritoran, a synthetic TLR4 antagonist, failed 
to show a benefit in reducing mortality in patients with 
severe sepsis as an adjunct to antibiotics, early goal directed 
therapy plus/minus APC, regardless of disease severity, 
site or organism (116). In roughly 50% of cases there was 
a pulmonary source of infection, but subgroup analysis of 
this cohort did not demonstrate any benefit. In the phase 1 
trial as in the animal model above, when given immediately 
prior to lipopolysaccharide injection, the TLR4 antagonist 
successfully attenuated both the clinical symptoms and the 
elevation in biomarkers of inflammation associated with the 
lipopolysaccharide (117). These findings overall suggest that 
antagonism of TLRs may reduce initiation of the harmful 
inflammatory cascade, but cannot adequately downregulate 
this once the process has been triggered, which clearly 
limits the clinical utility.
Research into TLR agonism has focused on prophylaxis 
of infection either by enhancing response to vaccination 
or in lieu of a vaccine. TLR2, TLR4 and TLR5 agonist 
treatment prior to infection has improved survival in murine 
models of S. pneumoniae, influenza A and Pseudomonas 
aeruginosa pneumonia, respectively (118-121), primarily by 
promoting neutrophil recruitment thus enhancing pathogen 
clearance. A similar strategy may possibly have therapeutic 
implications since the administration of a TLR5 agonist 
together with antibiotics at 12 h post infection with S. 
pneumoniae enhanced bacterial clearance and reduced lung 
injury (122). However, murine studies have demonstrated 
that the magnitude of resistance to infection is less with 
individual TLR agonism and the effect can be enhanced 
with synergistic TLR agonist administration (123) or use of 
aerosolized non-typeable Haemophilus influenzae lysate (124). 
Using this strategy in a murine acute myeloid leukemia 
model with or without chemotherapy-induced severe 
neutropenia, a single prophylactic inhaled dose of TLR2/6 
and TLR9 agonist was able to clear pulmonary bacterial 
loads and improve survival in P. aeruginosa, S. pneumoniae 
and Aspergillus fumigatus infection (125), suggesting that 
TLR agonism can induce important immune effector 
functions that are independent of neutrophil recruitment 
and offers an important potential prophylactic option for 
immunocompromised hosts at risk of infection. Whilst 
TLR agonism clearly enhances pathogen clearance in 
murine models, it is less clear what the impact of TLR 
agonism on pathogen clearance and lung injury is in clinical 
practice and the results of human trials are eagerly awaited.
PARs
Given the position of PARs at the interface between 
coagulation and inflammation, which as discussed is 
implicated in the injurious host response to an infectious 
stimulus and the development of ARDS (30,33), these 
agents may be suitable as adjuvants in the treatment 
of pneumonia to protect against or reduce lung injury. 
However, their divergent effects make therapeutic 
manipulation challenging and further characterization of 
their effect over time in the context of acute infection is 
required. In preclinical work, PAR-1 knockout mice had 
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increased early survival following S. pneumoniae pulmonary 
infection, with reduced pulmonary and blood bacterial 
loads (126). Furthermore, use of a highly specific PAR-1 
antagonist (SCH530348) reduced neutrophil recruitment to 
the lungs of mice infected with S. pneumoniae and decreased 
alveolar leak without compromising host defense (33). In 
the context of peritoneal sepsis, further studies using PAR-1 
agonists and antagonists have shown a variable mortality 
effect dependent on the time following infection, with 
PAR-1 detrimental early on, but beneficial in later stages of 
infection (127). 
More recently the cardiovascular morbidity and 
mortality associated with pneumonia has been an important 
focus of research and since PAR-1 antagonism inhibits 
platelet aggregation in humans, and in the context of S. 
pneumoniae infection PAR-1 antagonism inhibits in vitro 
neutrophil-platelet heterotropic aggregates induced by 
pneumolysin (34), this method of action could in addition to 
reducing neutrophilic inflammation offer cardioprotection 
to infected individuals. An important consideration 
though is that platelet inhibition increases risk of 
bleeding. However in the studies that demonstrated 
that PAR-1 antagonism significantly increased the risk 
of intracranial haemorrhage in patients with previous 
stroke, it is important to note that these individuals were 
already on dual anti-platelet therapy (128). As yet, work 
in the field of CAP and ARDS remains in the preclinical 
phase.
Stem cells
Preclinical studies have shown that mesenchymal stem cells 
(MSCs) have multiple immunomodulatory effects. MSCs 
are immunoregulatory by direct cell-cell interaction, by 
paracrine signaling and by generation of regulatory T 
cells (129), they are immunomodulatory by reprogramming 
macrophages to an anti-inflammatory IL-10-secreting 
phenotype (130), and they have both direct and indirect 
antimicrobial effects (131). They are recruited to sites of 
active inflammation and their activity can be modulated by 
inflammatory cytokines, TLRs and bacteria. Additionally, 
they have only low-level immunogenicity meaning 
allogeneic MSCs may be a viable therapy without the 
need for immunosuppression. Animal models appear to 
demonstrate reduction in bacterial load and attenuation of 
end-organ damage including to the lung in sepsis models, 
but with variable effects on mortality, which seem to be 
influenced by dosing regimen and timing related to the 
course of infection (132). In Europe, the SEPCELL project 
has been established to investigate the potential of stem cell 
therapy in CAP-induced sepsis in phase Ib/IIa clinical trials 
and the outcomes of these studies are awaited (133).
Neutralising pneumolysin
Pneumolysin is a pneumococcal virulence factor that is 
cytotoxic to the respiratory epithelium causing direct lung 
injury allowing bacterial spread. Additionally it inhibits 
normal immune responses, for example by preventing 
dendritic cell maturation and therefore recruitment of 
adaptive immunity (134,135), and promotes the formation 
of neutrophil-platelet aggregates that may potentially 
contribute to cardiovascular complications in individuals 
with S. pneumoniae CAP (34). In preclinical mouse 
models of pneumococcal pneumonia two strategies have 
been demonstrated to be beneficial. Administration of 
neutralising monoclonal antibodies prior to infection with 
S. pneumoniae succeeded in increasing survival time and 
bacterial clearance from the lung and reducing bacteremia 
and histological evidence of lung injury (136), whilst a 
detoxified pneumolysin derivative antigen successfully 
induced neutralising antibodies that decreased the 
inflammatory response and lung injury associated with S. 
pneumoniae infection (137).
Neutrophil elastase inhibitors
Neutrophil elastases are released on degranulation, 
degrading phagocytosed proteins. However during 
infection normal regulation by proteases including alpha-1 
antitrypsin can become overwhelmed allowing neutrophil 
elastases to promulgate lung injury by direct epithelial cell 
cytotoxicity in addition to impacting on both destruction 
and accumulation of the extracellular matrix, as well as 
prolonging the inflammatory response (138). Additionally 
there is evidence that neutrophil elastase activity can persist 
even after clinical improvement from an infection (139) 
and can drive the pathogenesis of both emphysema and 
pulmonary fibrosis post-infection (140). 
In Japan, sivelestat, a neutrophil elastase inhibitor, is in 
clinical use for pneumonia-associated ARDS following 
an initial phase III trial that suggested benefit in these 
patients (141).  However subsequently STRIVE, a 
multinational RCT, showed no improvement in mortality, 
ventilator-free days or pulmonary function in mechanically 
ventilated patients with acute lung injury of any aetiology 
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given sivelestat (142). The trial was discontinued 
prematurely in view of a trend of increased long-term 
mortality in the sivelestat arm. A number of studies since 
have also failed to demonstrate tangible benefit with a 
meta-analysis of 8 trials of sivelestat for ARDS of varying 
aetiologies showing no reduction in 28- to 30-day mortality 
including in subgroup analysis of only Japanese studies, a 
suggestion of decreased 180-day mortality in the placebo 
arms of borderline statistical significance, no impact on 
ventilator-free days, and only a minor improvement in 
paO2:FiO2 at day 3 (143). A recent Japanese retrospective 
observational study of severe pneumonia patients also 
showed no difference in 7- or 30-day mortality in patients 
receiving sivelestat in propensity matched groups. Due to 
the lack of benefit identified in the latest studies sivelestat is 
unlikely to be used in patients with severe pneumonia.
Summary
As demonstrated by Austrian and Gold, the single best 
intervention in terms of reducing mortality in pneumonia 
is effective antimicrobial therapy and therefore timely and 
appropriate microbiological sampling and antimicrobial 
administration will continue to be of the essence. However 
there remains a high mortality in patients with severe CAP 
despite antimicrobial administration mandating the search 
for adjunctive immunomodulatory therapies for CAP and 
the associated sequelae sepsis and ARDS. Despite much 
promise in pre-clinical work, many clinical trials have 
unfortunately failed to demonstrate a benefit and there are 
a number of areas where the data has been conflicting, for 
example PROWESS versus PROWESS-SHOCK, and 
CAPTIVATE versus phase II rTFPI data. Current evidence 
supports the use of macrolide combination antibiotic 
therapy and unless contraindicated continuation of pre-
admission statin and antiplatelet therapy, and suggests it 
may be reasonable to consider low dose corticosteroids 
for a minimum of 7 days following an initial bolus on 
an individual basis in patients with severe CAP and a 
hyperinflammatory phenotype given the potential for 
improving patient-centered and economic outcomes with 
negligible adverse effects. Additionally, a growing body 
of available evidence does not support the use of drugs 
such as sivelestat. Results of RCTs evaluating aspirin, IVIg 
and thrombomodulin are awaited and may yet influence 
practice, whilst there are other areas deserving of similar 
trials. Further away, there are a number of significant 
causes for optimism in preclinical studies, which need to be 
developed to permit clinical trials.
Moving forwards, in addition to pursuing these 
potential therapeutic targets for immunomodulation, there 
are a number of areas worthy of study. Firstly, current 
determination of CAP severity is based on crude scoring 
systems or criteria, whereas to derive optimal benefit from 
immunomodulatory strategies used in clinical practice to 
date we need to be able to reliably identify patients with 
or at risk of developing significant immune dysregulation, 
which requires adequately evaluated biomarkers. This 
both enables identification of patients likely to benefit 
from a therapy, but also facilitates more homogenous trial 
populations increasing the likelihood of positive outcomes. 
Secondly, nebulized and inhaled routes of administration 
enable delivery of the drug to the intended site of action 
with the potential to reduce systemic adverse effects 
and may well be utilized for a growing number of these 
adjunctive therapies. Thirdly, as we understand more about 
the pathogenesis of specific infections, it may be that the 
optimum strategy for adjunctive therapies differs with each, 
making early identification of the causative pathogen of 
even greater importance. Finally, for a number of these 
interventions, timing appears to be crucial, reflecting the 
evolution of inflammatory responses over the course of 
infection and the challenges in reversing inflammation 
and tissue damage. This means that rather than adjunctive 
treatments, a number of these therapies are best placed as 
prophylactic measures given during identified high risk 
periods to high risk individuals.
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